Incyte Q4 revenue growth beats estimates on demand for Jakafi

Incyte

10/02/2026 12:07

Overview

Biopharmaceutical firm's Q4 revenue rose 28% yr/yr, beating analyst expectations

Adjusted EPS for Q4 missed analyst expectations

Company's revenue growth driven by demand for Jakafi and Opzelura

Outlook

Incyte projects 2026 total net product revenue between $4.77 bln and $4.94 bln

Company expects Jakafi net product revenue of $3.22 bln to $3.27 bln in 2026

Incyte anticipates Opzelura net product revenue of $750 mln to $790 mln in 2026

Result Drivers

PRODUCT DEMAND - Increased demand for Jakafi and Opzelura drove net product revenue growth in Q4 2025

NEW PRODUCT UPTAKE - Strong uptake of Niktimvo and Zynyz contributed to revenue growth

MILESTONE REVENUE - Milestone and contract revenue added $100 mln to Q4 total revenue

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$1.51 bln
$1.35 bln (20 Analysts)
Q4 Adjusted EPS
Miss
$1.80
$1.93 (17 Analysts)
Q4 EPS
$1.46
Q4 Adjusted Operating Income
Miss
$451.42 mln
$473.06 mln (10 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 14 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Incyte Corp is $108.50, about 0.5% below its February 9 closing price of $109.03

The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 12 three months ago

Press Release: ID:nBwbbn8FRa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)